MedTrace Logo

Virtual Reality Exposure Therapy for Public Speaking Anxiety

NCT03885414 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-01-23

No results posted yet for this study

Summary

Virtual Reality exposure therapy (VRET) is an efficacious treatment for anxiety disorders but has yet to be implemented in regular care settings. This is arguably due to the limitations of the past generation of VR technology, which was expensive, inaccessible, cumbersome and hard to use. With the advent of consumer VR technology, VRET is now ready for implementation in regular care. This multiple-baseline trial will examine the effectiveness of VRET for public speaking anxiety (PSA) when delivered under real-world conditions at an ordinary, non-specialized mental health clinic, by clinical psychologist with only brief VRET training. Participants will either be self-referred specifically for this treatment, or come through ordinary clinical channels. Self-rated PSA will serve as primary outcome measure and will be measured three times prior to treatment (at screening and twice after a diagnostic screening telephone interview) , four times after onset, at the end of the treatment period, and three months after treatment.

Conditions

  • Public Speaking
  • Social Anxiety
  • Social Anxiety Disorder, Performance Only

Interventions

BEHAVIORAL

In-session Virtual Reality exposure therapy

A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.

BEHAVIORAL

Internet-administered transition program

Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.

Sponsors & Collaborators

  • PBM

    collaborator UNKNOWN

  • Mimerse

    collaborator UNKNOWN

  • Stockholm University

    lead OTHER

Principal Investigators

  • Per Carlbring, PhD · Stockholm University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-14
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03885414 on ClinicalTrials.gov